February 13, 2017
Ipsen acquires Sanofi’s five products for €83M
Ipsen has entered into a definitive agreement to acquire Sanofi’s five consumer healthcare products in certain European territories.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sanofi
February 9, 2017
Regeneron full year, quarter income up, global Praluent full year sales jump from $11M to $116M
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.
February 9, 2017
Sanofi, Regeneron can sell Praluent in the US during the appeal on Amgen’s patent claims
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
February 8, 2017
Sanofi’s 2016 income slightly down
Sanofi has reported net income of €1,6 billion for Q4 2016 which is 6% down compared to the same period last year. The full year income was €7.3 billion, 0.9% down from the last year.
February 8, 2017
Zealand gets $3.3M from Sanofi’s sales of Lyxumia
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
February 1, 2017
Sanofi wins approval for its two drugs in North America
Sanofi announced on Wednesday two approvals for its drugs in North America. Rheumatoid arthritis drug, which it has made in cooperation with Regeneron Pharmaceuticals, has been approved by Health Canada and the U.S. Food and Drug Administration (FDA) has approved Xyzal Allergy 24HR
January 30, 2017
Sanofi welcomes Kathleen Tregoning to its Executive Committee
Sanofi has appointed Kathleen Tregoning, Biogen’s senior Vice President of Corporate Affairs, as a new member of the Executive Committee, effective February 27, 2017.
January 20, 2017
Where do you stand against influenza
Flu, or influenza, is a very contagious, acute, viral respiratory infection. Influenza viruses vary in a high degree. The extent…
January 20, 2017
Sanofi’s M&A misses frustrate some investors in drugmaker
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
January 18, 2017
EC’s approval for Sanofi’s Suliqua triggers $10 million payment to Zealand Pharma
Zealand Pharma has announced a $10 million milestone payment following Sanofi’s announcement of European Commission marketing authorization in Europe for…